Paul Hastings Reps Korean Drug Co. In $126M GSK Deal

Law360, New York (May 11, 2010, 12:08 PM EDT) -- GlaxoSmithKline PLC announced Tuesday it would pay KRW142.9 billion ($125.9 million) for a stake in South Korean drugmaker Dong-A Pharmaceuticals Co. Ltd., in an effort to expand into the Asian pharmaceutical market.

The U.K. pharmaceutical giant agreed to buy 9.9 percent of the equity in Dong-A, South Korea's largest drug manufacturer, according to a GlaxoSmithKline filing with the U.S. Securities and Exchange Commission.

GlaxoSmithKline said the collaboration would give the company a chance to further capitalize on the expanding South Korean pharmaceutical market, the 13th-largest in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.